Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | ACP3 | P15309 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172115 | 0.88 | FFAR1 (0.43) | FFAR1ACP3CYP2C19GABBR2GABBR1 | |
| SCHEMBL339393 | 0.84 | ACP3 (0.42) | FFAR1ACP3CYP2C19GABBR2GABBR1 | |
| SCHEMBL339717 | 0.79 | ACP3 (0.44) | ACP3LMNAPOLBMEN1KMT2A | |
| SCHEMBL2173719 | 0.79 | ACP3 (0.46) | FFAR1ACP3CYP2C19GABBR2GABBR1 | |
| SCHEMBL3817936 | 0.76 | ACP3 (0.63) | ACP3LMNAPOLBSRC | |
| SCHEMBL2171520 | 0.76 | ACP3 (0.46) | FFAR1ACP3CYP2C19GABBR2GABBR1 | |
| SCHEMBL2172087 | 0.75 | ACP3 (0.44) | ACP3LMNAPOLBMEN1KMT2A | |
| SCHEMBL11297322 | 0.74 | ACP3 (0.61) | ACP3CYP2C19GABBR2GABBR1SRC | |
| SCHEMBL2351909 | 0.74 | ACP3 (0.43) | ACP3GABBR2GABBR1LMNAPOLB | |
| SCHEMBL30481345 | 0.74 | ACP3 (0.39) | ACP3LMNAPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097753-B2 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | CLARIANT FINANCE (BVI) LIMITED (VG) | 2012-01-17 | — | — | US | disclosed |
| US-20070213436-A1 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | CLARIANT INTERNATIONAL LTD | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213436-A1 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | PAH, ALKBH3, FTO | FFAR1 32/4885ACP3 3182/4885CYP2C19 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.